Pioglitazone Attenuates Atherosclerotic Plaque Inflammation in Patients With Impaired Glucose Tolerance or Diabetes

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.

Allard C. van der Wal, A E Becker, Chris M. van der Loos et al. · Circulation · 1994 · 1.9K citations · Full text

Medicine, Cardiology, Pathology +17

Imaging Atherosclerotic Plaque Inflammation With [ ¹⁸ F]-Fluorodeoxyglucose Positron Emission Tomography

James H.F. Rudd, Elizabeth A. Warburton, Tim D. Fryer et al. · Circulation · 2002 · 1.2K citations

Medicine, Nuclear Medicine, Radiology +17

In Vivo 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Provides a Noninvasive Measure of Carotid Plaque Inflammation in Patients

Ahmed Tawakol, Raymond Q. Migrino, Gregory Bashian et al. · Journal of the American College of Cardiology · 2006 · 904 citations

Medicine, Nuclear Medicine, Radiology +13

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

Steven E. Nissen, Stephen J. Nicholls, Kathy Wolski et al. · JAMA · 2008 · 847 citations

Medicine, Pharmacology, Pharmacotherapy +17